KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.

Francesco Mannelli, Giacomo Gianfaldoni, Paola Guglielmelli, Francesco Buccisano, Roberto Caporale, Marco Chiarini, Giuseppe Rossi, Adriano Venditti, Paola Fazi, Enrico Crea, Alfonso Piciocchi, Maria Teresa Voso, Marco Vignetti, Sergio Amadori, Alessandro Maria Vannucchi

Future Oncol 17(29) 3787-3796

PMID34254530
PMCID-
DOI10.2217/fon-2021-0388
发表日期2021-07-13
入排依据:The record describes the protocol/design of a Phase III randomized oncology trial and an early biomarker study within it. It does not report the primary or secondary time-to-event efficacy outcomes (survival, progression, etc.) required for inclusion in a Kaplan-Meier digitization cohort.
摘要

摘要

AMELIORATE is a Phase III, randomized trial aiming to personalize treatment intensity in FLT3-mutated acute myeloid leukemia. The current study provides an early appraisal of chemosensitivity based on peripheral blasts clearance, as assessed by multiparameter flow cytometry, from baseline to day 4 of induction. This biomarker was previously demonstrated to predict complete remission achievement and measurable residual disease status. For patients experiencing low peripheral blast cells (i.e., ≤2.0 logs), two major adjustments of treatment as compared with current standard of care are envisioned in the experimental arm: the immediate switch to intensified induction with high-doses cytarabine (1500 mg/m2 b.i.d. on days 5-7 of induction); and the early allocation of the patient to high-risk disease category, to be further refined later based on postinduction measurable residual disease status.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。